SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Sonny Liston — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSonny Liston
Date of birth1932-05-08
IdentifiersMRN HR-BX007-SYN-TD; SSN (made up) 000-07-8853
Document date1969-07-21
AuthorMalcolm Achebe-Whitford, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week review of blood pressure and drinking. [S]

History of Present Illness

Sonny Liston returns four weeks after starting amlodipine 5 mg and valsartan 160 mg. He has taken it every morning and can say what it is for and when to take it. He did not send home readings for the first two weeks: the clinic had asked him to photograph the monitor and send the picture, and the steps on the phone were confusing. After a nurse called him in the third week he began reading the numbers out on the clinic voice line; the last seven mornings average 134/84 mmHg. No dizziness or ankle swelling. Drinking is down to about 15 drinks a week, but he still has five or six on Saturday nights and finds he cannot stop once he starts; he asks for the medicine he was told about. No thoughts of suicide. [S]

ElementDetail
Home readingsAverage 134/84 mmHg over the last seven mornings
Potassium and creatinine4.4 mmol/L and 1.1 mg/dL
AUDIT-C7
Teach-backCorrect with the picture card

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest pain, palpitations or ankle swelling
NeurologicalNegativeNo dizziness or headaches
GastrointestinalNegativeNo abdominal pain, nausea or yellowing
PsychiatricNegativeMood all right; no thoughts of suicide

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg and valsartan 160 mg combined oral tablet, one tablet each morningOne tablet each morningOral route1969-06-23 to 1969-07-21completedS
Amlodipine 10 mg and valsartan 160 mg combined oral tablet, one tablet each morningOne tablet each morningOral route1969-07-21activeS
Naltrexone 50 mg oral tablet, one tablet each morningOne tablet each morningOral route1969-07-21activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1969-07-21Body height185cmS
1969-07-21Body weight98kgS
1969-07-21Body mass index (BMI) [Ratio]28.6kg/m2S
1969-07-21Systolic blood pressure136mm[Hg]S
1969-07-21Diastolic blood pressure86mm[Hg]S
1969-07-21Heart rate58/minS
1969-07-21Respiratory rate14/minS
1969-07-21Body temperature36.6CelS
1969-07-21Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1969-07-21Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
1969-07-21Creatinine [Mass/volume] in Serum or Plasma1.1mg/dL0.74-1.35 mg/dLNormalS
1969-07-21Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1964)/1.73 sq M89mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1969-07-21Total score [AUDIT-C]7{score}S

Physical Exam

Vital signs recorded on 1969-07-21; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 136/86 mmHg (average of two); pulse 58; weight 98.0 kg
CardiovascularRegular rhythm; no edema
AbdomenLiver not enlarged; no tenderness

Problems

ProblemClinical statusVerificationCodeProvenance
High blood pressure readings at a first visit (154/98 mmHg, average of two readings with a large cuff), without a diagnosis of hypertension; out-of-office confirmation neededresolvedconfirmed R03.0S — Synthetic presenting finding; resolved into the diagnosis at the consultation visit when ambulatory monitoring confirmed hypertension.
Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (daytime average 146/94 mmHg, nighttime 132/84 mmHg), with mild concentric left ventricular hypertrophy on echocardiography and normal kidney function and urine albuminactiveconfirmed I10S — Synthetic modern diagnosis; no hypertension is documented in his life.
Alcohol use disorder, moderate (four DSM-5-TR criteria: drinking more than intended, unsuccessful efforts to cut down, craving, and continued drinking despite its effect on his training, blood pressure and liver tests); AUDIT 16activeconfirmed F10.20S — Synthetic modern diagnosis by interview, anchored to the description of heavy drinking; not a historical diagnosis.
Personal history of physical abuse in childhood (beaten regularly by his father), with heavy field work from the age of eightactiveconfirmed Z62.810S — Synthetic coding of the documented childhood history; physical abuse only.
Does not read or write (no schooling as a child); prefers spoken explanations, pictures and demonstrationsactiveconfirmed Z55.0S — Synthetic coding of the documented literacy, recorded so that care is adapted.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationOffice blood pressure (seated, large cuff, average of two readings), weight and BMI, heart soundsEvery visitCompleted today136/86 mmHg; weight 98.0 kg
ExaminationOut-of-office blood pressure (ambulatory or home monitoring)At diagnosis and after each treatment changeDeferredDeviation: home readings were asked for each morning from the start of treatment but none arrived for two weeks, because the photo-upload steps were not usable for him and teach-back had not covered them. Office and later home readings agree, so no harm is known. Corrective action: readings by voice message, shown with teach-back by the nurse; seven readings in the last week averaged 134/84 mmHg
LaboratoryPotassium, creatinine and eGFRBaseline; two to four weeks after starting an ARB; then every six months on an ARBCompleted todayPotassium 4.4 mmol/L, creatinine 1.1 mg/dL, eGFR 89, four weeks after starting valsartan; next in about six months
LaboratoryLipids, glucose or A1c, urine albumin-to-creatinine ratio, TSHAt diagnosis, then yearly (TSH at diagnosis)Up to dateDone at intake; next yearly
ImagingEchocardiogramAt diagnosis for stage 2 hypertension or suspected LVH; repeat as indicatedUp to dateMild LVH at two weeks; repeat in about a year to look for regression with control
Medication safetyAntihypertensive tolerance (ankle edema, dizziness) and adherence by teach-backEach follow-up and each dose changeCompleted todayNo dizziness or edema on 5/160 mg; teach-back correct; dose raised today with a new picture card
ReferralFitness to compete (AHA/ACC athlete statement)At diagnosis and before returning to competitionUp to dateNot yet controlled; no bouts
SurveyDrinking (AUDIT-C, drinks per week, drinking days)Every follow-up during treatment; full AUDIT at about four monthsCompleted todayAUDIT-C 7; about 15 drinks a week, with heavy Saturday nights
LaboratoryLiver tests (AST, ALT, GGT)Baseline; about two months after starting naltrexone or cutting down; then as indicatedOrderedIntake AST 46, ALT 38, GGT 88 U/L; recheck in about two months on naltrexone
Medication safetyNaltrexone: nausea, liver tests, and opioid-blockade wallet cardEach follow-up after startingCompleted todayStarted today; no opioid use; wallet card given
SurveySuicide-risk review (structured questions) and safety planEvery visitCompleted todayNo thoughts of suicide
Self-managementHealth literacy: teach-back, picture card, read-aloud consent, voice remindersEvery visitCompleted todayTeach-back of the new dose and of naltrexone correct; voice-message readings set up

Goal progress:

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension and depression monographs (2026); The Healthcare Professional's Core Resource on Alcohol (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition (2024)

Follow-up: Preventive visit in three weeks. Three-month review in two months with liver tests and AUDIT-C. Call 988 or the clinic at any time if thoughts of suicide arise. Next scheduled visit 1969-08-11: periodic adult preventive visit. [S]